18个点左右多一点不到19个点那到今年我们的光化率已经提升到了25个点那就从侧面上反映了这个非信息渠道的需求不断的在成长 呃先引渠道那肯定都是由于这个叫做呃现在特别是餐饮店啊的这个数量的一个减少我们看到了今年特别是一些个体为投资人的这个小的小型的餐饮店必定于是比较高的啊然后呢在今年呢呃以餐饮公司啊有这个 投资人的这样的一个背景的这些连锁餐饮在今年有的还在做了一些扩张所以变化还是有一些不一样但整体上来看今年的餐饮数字大家其实之前也看到好多城市披露出来都是非常我们也是有点掉眼镜的 明白明白然后这边有投资者委托我请教一下更主要就是怎么看待当前一些新渠道的这样一些发展机会比如说今年比较火的像会员超市这些商务这些包括可能就是最近比较火的像微型小店这些渠道就是怎么看待这一块对啤酒行业的影响以及我们怎么去考虑在这一块去做布局 首先我们肯定会积极的去拥抱我们的这些新的一些非现影渠道的一些变化这个其实就是反映了在现影渠道或者是我们要通过加价去买消费情绪的这些渠道在目前受到的这样的影响从而给我们整个包括啤酒在内的其他很多这样的一些 消费场景带来了一个比较大的一个变化那我们在今年呢也把这个我们的嗯渠道啊做出了重新的一个划分那比如说 ...

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector in China, highlighting significant growth in the number of IND applications and new drug approvals. Core Insights - Since 2017, the number of IND applications for Class 1 new drugs has been steadily increasing, with a notable 31.7% year-on-year growth in 2023, reaching 1241 applications [5][22] - The number of Class 1 new drugs approved for market in China nearly doubled from 2022 to 2023, increasing from 9 to 35, representing a growth rate of 289% [7][10] - The focus of innovative drug development is primarily on oncology and immunotherapy, with these areas accounting for 64.4% of the total new drug sales [70] Summary by Sections Section 1: Current Status of Pharmaceutical Innovation in China - The report notes a significant increase in IND applications for Class 1 new drugs, attributed to supportive government policies and a recovering economic environment [5][22] - The proportion of biological products in IND applications has stabilized at around 48.3%, while innovative chemical drugs have seen a slight decline [15][22] Section 2: Growth of Marketed Innovative Drugs - The number of marketed Class 1 innovative drugs has shown a consistent upward trend, with a substantial increase in 2023 [7][10] - The distribution of therapeutic areas for new drugs shows a strong emphasis on oncology and immunology, which are currently the hottest research fields [10][70] Section 3: IND Application Trends - The report highlights a 16.4% increase in the number of first-time IND applications in 2023, with a compound annual growth rate (CAGR) of 25.1% over the past four years [22][25] - The report identifies a growing interest in small molecule drugs and antibody therapies, with CGT (cell and gene therapy) and ADC (antibody-drug conjugates) showing significant growth rates [25][51] Section 4: Internationalization of Domestic Innovative Drugs - The report discusses the increasing number of Chinese companies successfully bringing their innovative drugs to international markets, with 33 license-in and 78 license-out transactions in 2023 [58][67] - Notable approvals by the FDA for Chinese-developed drugs indicate a growing recognition of domestic innovation capabilities [68][70]